Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy

Higashi, Taishi; Hayashi, Hiromitsu; Taki, Katsunobu; Sakamoto, Keita; Kuroki, Hideyuki; Nitta, Hidetoshi; Hashimoto, Daisuke; Chikamoto, Akira; Beppu, Teruhiko; Baba, Hideo

doi:10.1007/s10147-015-0898-0

Cited by 54 publications

(44 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Muscle atrophy has been reported to be a prognostic risk factor for survival of HCC patients treated with living donor liver transplantation, resection, and sorafenib, as well as LC patients classified as CP‐A or CP‐B . Furthermore, muscle function loss has been reported to have a close relationship with cognitive function .…”

Section: Discussionmentioning

confidence: 99%

Easy surveillance of muscle volume decline in chronic liver disease patients using finger‐circle (yubi‐wakka) test

Hiraoka

Izumoto

Ueki

et al. 2019

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Muscle atrophy (MA) and muscle strength decline are important clinical features in chronic liver disease (CLD) patients. An easy to perform MA screening method without need for special equipment would be helpful. We evaluated the usefulness of the previously reported finger‐circle test as screening for MA in CLD patients. Methods We retrospectively enrolled 358 Japanese CLD outpatients (70.8 ± 10.2 years, male/female = 234/124) who had undergone a computed tomography examination from December 2017 to March 2018, of whom 137 had chronic hepatitis, 169 had liver cirrhosis Child–Pugh A, and 52 had liver cirrhosis Child–Pugh B/C. Bilateral psoas muscle area at the middle of the third lumber vertebra (L3) was evaluated with computed tomography findings, which was performed as a screening of hepatocellular carcinoma, using a previously reported parameter for MA [psoas index (PI): total psoas muscle area (cm 2 )/height (m) 2 ] [mean PI ± standard deviation (SD) of male patients: 6.50 ± 1.13 cm 2 /m 2 and those of female patients: 4.30 ± 0.90 cm 2 /m 2 ]. We then evaluated the correlation between MA and finger‐circle test results in these patients. Results The mean PI values for finger‐circle test results Bigger, Just‐fits, and Smaller were 5.64 ± 1.34, 5.00 ± 1.25, and 4.83 ± 1.46 cm 2 /m 2 , respectively, in male patients ( P < 0.001) and 4.31 ± 1.06, 3.93 ± 0.97, and 3.42 ± 0.94 cm 2 /m 2 , respectively, in female patients ( P = 0.001). We found that a finger‐circle test result in male patients other than Bigger (Just‐fits and Smaller) predicted a decline in psoas muscle area of L3 to PI 5.25 cm 2 /m 2 (sensitivity/specificity 0.619/0.667, area under the curve 0.654, 95% confidence interval 0.583–0.724), which was approximately mean minus 1 SD (5.37 cm 2 /m 2 ). On the other hand, a Smaller test result in female patients predicted a decline in psoas muscle area of L3 to PI 3.33 cm 2 /m 2 (sensitivity/specificity 0.740/0.583, area under the curve 0.698, 95% confidence interval 0.583–0.813), approximately mean minus 1 SD (3.40 cm 2 /m 2 ). Conclusions The finger‐circle test is an easy to perform and effective screening method for predicting earlier stage of MA in CLD patients without the need for special equipment.

show abstract

Section: Discussionmentioning

confidence: 99%

Easy surveillance of muscle volume decline in chronic liver disease patients using finger‐circle (yubi‐wakka) test

Hiraoka

Izumoto

Ueki

et al. 2019

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

show abstract

“…In patients with CLD, sarcopenia, MVL, and muscle strength decline are not rare, even in an early stage . In addition, MVL has recently been reported as a prognostic factor for survival in HCC patients treated with liver transplantation, surgical resection, or sorafenib, although few reports have elucidated the relationship between muscle function and prognosis of HCC patients following surgical resection. Although the difference was not statistically significant, the rate of postoperative infection was higher in patients with MVL than in those without that in the present study (11.4% vs 2.9%, P = 0.056), and our results also showed that MVL is an independent risk factor for death in HCC patients treated with resection.…”

Section: Discussionmentioning

confidence: 99%

“…Hepatocellular carcinoma (HCC) is the second most common cause of cancer‐related death worldwide and often develops in patients with CLD. In patients with both liver cirrhosis and HCC, MVL has been reported to be an independent risk factor for death . However, there have been few investigations of the relationship of muscle function with prognosis of HCC patients treated with surgical resection.…”

Section: Introductionmentioning

confidence: 99%

Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma

Hiraoka

Otsuka

Kawasaki

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…In the USA, sarcopenia reportedly occurs in 40–70% of patients with cirrhosis, which is a higher prevalence than among patients with inflammatory bowel disease (approximately 20%) . In Japan, sarcopenia incidence among patients with cirrhosis has been reported to range from 10% to 70% …”

Section: Epidemiology and Clinical Significance Of Sarcopenia In Livementioning

confidence: 99%

Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria

Nishikawa

Shiraki

Hiramatsu

et al. 2016

Hepatology Research

491

713

View full text Add to dashboard Cite

Sarcopenia is defined by muscle loss and muscle dysfunction. Sarcopenia is classified into primary and secondary types, based on the cause. Primary sarcopenia is mainly aging-related sarcopenia, whereas secondary sarcopenia is the reduced muscle mass and strength that accompanies an underlying disease. Given the essential role of the liver in metabolism, secondary sarcopenia due to nutritional disorders or other factors can frequently occur in liver disease. In 2015, the Japan Society of Hepatology (JSH) decided to establish its own assessment criteria for sarcopenia in liver disease because the number of liver disease patients with sarcopenia is expected to increase and there is cumulative evidence to indicate sarcopenic patients have poor clinical outcomes. A working group to create assessment criteria for sarcopenia has thus been established by the JSH. In this article, we summarize the current knowledge with regard to sarcopenia and present the assessment criteria for sarcopenia in liver disease proposed by the JSH (1st edition). To the best of our knowledge, this is globally the first proposed assessment criteria for sarcopenia specializing in liver disease.

show abstract

Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy

Abstract: Sarcopenia was a risk factor for postoperative complications after major hepatectomy, particularly in elderly patients.

Cited by 54 publications

References 42 publications

Easy surveillance of muscle volume decline in chronic liver disease patients using finger‐circle (yubi‐wakka) test

Easy surveillance of muscle volume decline in chronic liver disease patients using finger‐circle (yubi‐wakka) test

Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma

Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria

Contact Info

Product

Resources

About